Baxalta is classified as operating in the Surgical & Medical Instrument Manufacturing industry, NAICS Code 339112.
Baxalta is a publicly traded company on using the ticker symbol BXLT.
Detailed information on company financials and operating reports can be found here:
: BXLT
Note: Baxalta's revenues are gauged from an analysis of company filings.
Trademark Applications
Trademark applications show the products and services that Baxalta is developing and marketing.
Baxalta doesn't have any recent trademark applications, indicating Baxalta is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
BIOLIFE CELLULAR THERAPY SERVICES Medical services, namely, cellular starter material collection services
07/26/2022
INFUBASE Medical devices, namely, vial access system consisting primarily of a docking tray that facilitates direct access to contents of multiple vials containing pharmaceutical preparations for patient infusion.
04/04/2022
RECOMBINATE Pharmaceutical preparations and substances, namely medicine used to replace the clotting factor in hemophilia patients
09/24/2021
See all trademarks and details in the Full Report.
Market Share of Baxalta's Largest Competitors
A competitive analysis shows these companies are in the same general field as Baxalta, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Baxalta.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Baxalta and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.